Bioluminescence imaging correlates with tumor progression in an orthotopic mouse model of lung cancer

Madero-Visbal, Rafael; Colón, Jimmie; Hernandez, Ingrid C.; Limaye, Arati; Smith, Joshua S.; Lee, Christopher M.; Arlen, Philip A.; Herrera, Luis A.; Baker, Cheryl H.

doi:10.1016/j.suronc.2010.07.008

Cited by 34 publications

(22 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Madero-Visbal et al, it was reported that the median survival with one million A549 cells per mouse was around 60 days. 22 In these current studies, we increased the number of cells injected to five million cells per mouse, which resulted in a median survival of 32 days (Figure 1B). Quantified in vivo bioluminescence increased in the beginning as tumor cells grew, then plateaued, followed by a continuous increase until sacrifice.…”

Section: Resultsmentioning

confidence: 93%

Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2′-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles

Peng

Feng

Yuan

et al. 2014

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

The aims of these studies were to establish an orthotopic non-small-cell lung cancer (NSCLC) mouse model, and to investigate the therapeutic efficacy of lipid-based nanoparticles (NPs) containing 2′-(2-bromohexadecanoyl)-docetaxel (Br-C16-DX) in this new model. A novel orthotopic NSCLC model was established in nude mice through dorsal side injection of luciferase-expressing A549 cells. The model was characterized by survival study, histological staining, bioluminescence imaging and PET/CT imaging. The therapeutic efficacy of the Br-C16-DX NPs versus Taxotere® was investigated in this model. The results demonstrated that mouse survival time was significantly prolonged by weekly intravenous administration of the NPs or Taxotere. Furthermore, the NPs group had 35 days longer progression-free survival and 27 days longer median survival compared to the Taxotere group. It was concluded that the developed orthotopic NSCLC model represents a feasible, reproducible, and clinically-relevant experimental mouse model to test current and potential therapies including nanomedicines.

show abstract

Section: Resultsmentioning

confidence: 93%

Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2′-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles

Peng

Feng

Yuan

et al. 2014

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

show abstract

“…The genetic modification of organisms, such as viruses 1,2 , bacteria 3 , or small mammals 4 to either induce or constitutively express bioluminescence, has been highly successful and widely demonstrated [5][6][7] . Bioluminescence, an in vivo chemiluminescent reaction involving naturally occurring reagents, has the advantage of producing light without the need for an external light source.…”

Section: Introductionmentioning

confidence: 99%

A Step Beyond BRET: Fluorescence by Unbound Excitation from Luminescence (FUEL)

Dragavon

Sinow

Holland

et al. 2014

JoVE

View full text Add to dashboard Cite

Fluorescence by Unbound Excitation from Luminescence (FUEL) is a radiative excitation-emission process that produces increased signal and contrast enhancement in vitro and in vivo. FUEL shares many of the same underlying principles as Bioluminescence Resonance Energy Transfer (BRET), yet greatly differs in the acceptable working distances between the luminescent source and the fluorescent entity. While BRET is effectively limited to a maximum of 2 times the Förster radius, commonly less than 14 nm, FUEL can occur at distances up to µm or even cm in the absence of an optical absorber. Here we expand upon the foundation and applicability of FUEL by reviewing the relevant principles behind the phenomenon and demonstrate its compatibility with a wide variety of fluorophores and fluorescent nanoparticles. Further, the utility of antibody-targeted FUEL is explored. The examples shown here provide evidence that FUEL can be utilized for applications where BRET is not possible, filling the spatial void that exists between BRET and traditional whole animal imaging.

show abstract

“…Imaging systems recorded the spatial distribution of these scattered photons from the surface of the animal. Most of bioluminescent optical imaging systems provide 2-dimensional information in rodents121415 with signal quantification by subsequent ROI (Region Of Interest) analyses on the animal surface. 2-D imaging is simple and provides a good but only relative measure of the internal light source brightness.…”

mentioning

confidence: 99%

In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling

Mollard

Fanciullino

Giacometti

et al. 2016

Sci Rep

View full text Add to dashboard Cite

This study aimed at evaluating the reliability and precision of Diffuse Luminescent Imaging Tomography (DLIT) for monitoring primary tumor and metastatic spreading in breast cancer mice, and to develop a biomathematical model to describe the collected data. Using orthotopic mammary fat pad model of breast cancer (MDAMB231-Luc) in mice, we monitored tumor and metastatic spreading by three-dimensional (3D) bioluminescence and cross-validated it with standard bioluminescence imaging, caliper measurement and necropsy examination. DLIT imaging proved to be reproducible and reliable throughout time. It was possible to discriminate secondary lesions from the main breast cancer, without removing the primary tumor. Preferential metastatic sites were lungs, peritoneum and lymph nodes. Necropsy examinations confirmed DLIT measurements. Marked differences in growth profiles were observed, with an overestimation of the exponential phase when using a caliper as compared with bioluminescence. Our mathematical model taking into account the balance between living and necrotic cells proved to be able to reproduce the experimental data obtained with a caliper or DLIT imaging, because it could discriminate proliferative living cells from a more composite mass consisting of tumor cells, necrotic cell, or inflammatory tissues. DLIT imaging combined with mathematical modeling could be a powerful and informative tool in experimental oncology.

show abstract

Bioluminescence imaging correlates with tumor progression in an orthotopic mouse model of lung cancer

Cited by 34 publications

References 11 publications

Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2′-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles

Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2′-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles

A Step Beyond BRET: Fluorescence by Unbound Excitation from Luminescence (FUEL)

In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling

Contact Info

Product

Resources

About